Breast Cancer Stem Cells and Tumor Suppressor Genes  by Hwang-Verslues, Wendy W. et al.
J Formos Med Assoc | 2008 • Vol 107 • No 10 751
What are Stem Cells?
Stem cells, according to most widely accepted
concepts, are undifferentiated cells that can un-
dergo asymmetric cell division. Upon cell division,
a stem cell generates two daughter cells: one cell
is identical to the original stem cell and maintains
the stem cell characteristics (this is also known as
self-renewal); the other cell is more committed to
differentiation and formation of a different cell
linage. This distinct daughter cell undergoes sev-
eral divisions and differentiation processes and
finally forms a terminal differentiated cell. The
cells in the intermediate stages of the division and
differentiation processes are referred to as progen-
itor cells.1 Each of the progenitor cells can also
generate a spectrum of differentiated progeny;
however, their ability to self-renew and maintain
themselves in an undifferentiated stage is not as
persistent as that of stem cells.2
The number of cells in this hierarchy of pro-
genitor cells has to be tightly regulated in order
to form new tissue or reconstitute damaged tissue
while at the same time preventing uncontrollable
cell proliferation. The most well studied mamma-
lian stem cell hierarchical organization and regu-
lation is the hematopoietic stem cell lineage.3,4
In the hematopoietic system, there is one type of
hematopoietic stem cell which gives rise to mul-
tipotent progenitors. The multipotent progenitors
differentiate into two lineages: common lymphoid
progenitors and common myeloid progenitors.
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These progenitors in turn differentiate into all
types of mature blood cells.3 It has been shown
that the differentiation, self-renewal and mainte-
nance of quiescence in hematopoietic stem and
progenitor cells are regulated by multiple cell cycle
genes, such as cyclin-dependent kinase inhibitors
p21 and p27.5–8 Moreover, increasing evidence
suggests that paracrine cells from the microenvi-
ronment surrounding the stem cell (known as the
stem cell niche) as well as cell-cell and cell-matrix
interactions also contribute to the regulation of
stem cell self-renewal and differentiation.9,10 This
careful restriction of stem cell and progenitor cell
expansion and control of stem cell fate not only
maintains the hierarchical organization of the
stem and progenitor cells but also prevents hy-
perplasia or tumor formation. When transforma-
tion events take place, deregulated self-renewal
could occur in stem cells, and the progenitor cells
could regain self-renewal ability.3,11,12 The dereg-
ulated cell proliferation could result in leukemo-
genesis. Several studies in this field showed that
hematopoietic stem cells are the target of malig-
nant transformation, which gives rise to a variety
of leukemias.13–15 Some studies demonstrated
that stem cells may accumulate the mutations
that are required for neoplastic transformation;
however, the phenotypes of these mutations may
be shown in their primitive progenitors.16,17
Recently, Akala et al showed that hematopoietic
multipotent progenitors could regain their self-
renewal ability and become malignant with further
oncogenic mutations.11 This observation revealed
a new mechanism in the cancer stem cell hypoth-
esis of carcinogenesis (described in the cancer
stem cell section).
Mammary Stem Cells
The adult mammary gland is composed of at
least three cell lineages including myoepithelial
cells, ductal epithelial cells, and alveolar epithe-
lial cells. These cell types form the basal layer of
ducts and alveoli, line the lumen of the ducts, and
synthesize milk proteins respectively. Mammary
gland development and remodeling during pu-
berty, pregnancy, lactation and involution is com-
plex and dynamic. These processes include rapid
cell proliferation, differentiation and apoptosis.
A stem cell-like population residing in the mam-
mary gland could meet the need for cell prolif-
eration and cell replacement at various times. 
By analyzing the methylation status of polymor-
phic DNA markers on X-linked genes, Tsai et al
showed that in human breast tissue entire lob-
ules of the gland retain the same X-chromosome
inactivation pattern in all cell lineages. This sug-
gested a clonal origin of the mammary gland.18
Consistent with this result, Kordon and Smith uti-
lized the mouse mammary tumor virus (MMTV)
to infect, and thus mark, mammary epithelial
cells. They found that a single MMTV-marked
mammary epithelial cell could regenerate the 
entire mouse mammary gland.19 More recently,
this concept of a single mammary stem cell
being able to reconstitute the whole mammary
gland was validated by two studies using specific
surface markers and immunosorting to isolate
mammary stem cells from mice.20,21 In these
studies, several in vitro and in vivo analyses were
also performed to demonstrate that stem cells
are at the top of the hierarchy in mammary cell
lineages.
Techniques to isolate and enrich stem cells
from mouse and human mammary glands have
utilized the biological properties of stem cells 
to develop enrichment systems. Stem cells are
mainly quiescent and in the G0 state. They are
able to retain bromodeoxyuridine (BrdU) or 
3H-thymidime longer than the cycling cells.22,23
Also, stem cells express specific membrane gly-
coprotein transporters, such as ABCG2, which
allow them to exclude dyes such as Hoechst-
33342.24 Another interesting property is that
some stem cells, such as neural stem cells, can
grow in suspension in serum-free conditions and
form sphere-like structures.25 Taking advantage of
the first two properties, mammary stem cells can
be distinguished from other cells based on in-
creased retention of BrdU, (commonly referred to
as label retaining cells or LRCs). However, for best
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enrichment of stem cells, LRCs need to be further
screened by immunostaining of other stem cell
markers.26,27 Stem cells can also be distinguished
by Hoechst-33342 staining combined with flow
cytometry as the side population (SP) which ex-
cludes the dyes. Once these stem cell-enriched
populations are isolated, they are further char-
acterized and additional markers potentially use-
ful for stem cell identification can be tested. In
both human and mouse mammary glands, LRCs
and SP cells have been isolated and character-
ized.28–32 The SP cells had the potential to gener-
ate both luminal and myoepithelial lineages, and
could form branched structures in matrigel.30–32
When grown in vitro using serum-free condition,
these cells, similar to neural stem cells, could
form mammospheres.32,33 Most importantly, after
these cells were transplanted into cleared mouse
fat pads, they could generate a mouse mammary
gland.28
This type of research has identified a number
of surface markers useful in distinguishing mam-
mary stem cells from the bulk of mammary ep-
ithelial cells. Known stem cell markers such as
Bmi-1, cytokeratins 5/6, 14 and 19, EpCAM, p21,
mushashi-1, sialomucin (Muc), epithelial-specific
antigen (ESA) and CD10 have been used for
identification of normal human mammary stem
cells.30,31,33–36 In normal mouse mammary tissue,
Sca-1, α6 integrin (CD49f), β1 integrin (CD29),
various cytokines, and CD24 have also been used
as putative stem cell markers.20,21,37 These mark-
ers not only provide the means of stem cell isola-
tion but also serve as tools to identify stem cell
niches within the larger bulk tissue.
A stem cell niche is the place in a specific tis-
sue where the microenvironment is suitable for
stem cell function.3 Villadsen et al identified a
candidate mammary stem cell niche in ducts and
areas containing progenitor cells in lobules. They
found that putative stem cells in ducts were qui-
escent, but the progenitor cells in the lobules were
more active. Using stem cell markers ESA, Muc,
keratin 5 and lineage marker keratins 14 and 19
in combination with other assays, they showed 
a cell hierarchy in the mammary gland.38
Cancer Stem Cells
The concept of cancer stem cells has emerged
more recently and has led to new hypotheses
about tumor growth. Cancer stem cells share sim-
ilar properties with normal stem cells in terms 
of their capacity for self-renewal. They can self-
renew, cause tumorigenesis, recurrence, and metas-
tasis. Moreover, they can divide asymmetrically to
generate differentiated cancer cells. Within the
population of cancer cells, cancer stem cells are the
ones that can form new tumors, and their asym-
metric division contributes to the heterogeneity.
The first cancer stem cells were identified in
acute myelogenous leukemia (AML).39 It has been
shown that human AML stem cells could be iso-
lated using surface markers CD34 and CD38. The
CD34+CD38− cells from patient samples com-
prised only 0.2% in a patient, but they were the
only cells able to passage AML from human to
NOD/SCID mice. Recently, increasing experimen-
tal evidence has suggested that cancer stem cells
are also present in several solid tumors,2 such as
tumors in the breast,40 central nervous system,41
prostate,42 melanoma,43 colon,44,45 multiple mye-
loma,46 pancreas,47 and lung adenocarcinoma.48
Overall, more and more evidence is accumulating
in support of the cancer stem cell hypothesis,3
and the usefulness of stem cell characteristics in
understanding cancer progression.
With the emergence of the cancer stem cell
concept, there are two competing models to de-
scribe the heterogeneity of solid tumors. The tra-
ditional model postulates that most cancer cells
have the potential to proliferate extensively and
form tumors. In this case, stochastic changes
contribute to tumor heterogeneity. In contrast,
the newer competing model postulates that most
cancer cells lack the capacity for self-renewal 
and have only a limited potential to proliferate.
It is instead a subset of cancer cells which have
stem cell properties (i.e. cancer stem cells) and
can proliferate extensively.3 Although the precise
mechanism for cancer heterogeneity remains to
be elucidated, the distinct property of genomic
instability in cancer cells may contribute to this.
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Breast Cancer and Breast Cancer 
Stem Cells
Approximately 80% of breast cancers are invasive
ductal carcinomas, and 10–15% of breast cancers
are invasive lobular carcinomas. Additional rare
types constitute less than 5–10% of breast can-
cers. Microarray gene expression profiling pro-
vides one classification system for human breast
cancers.49–52 According to their gene expression
signatures, invasive ductal carcinomas can be clas-
sified into five subtypes: luminal A, luminal B,
ERBB2 (Her2/Neu), basal and normal-like. The
luminal subtypes are mostly estrogen receptor
(ER)-positive. The low-grade and low-proliferation
luminal A tumors are sensitive to hormonal ther-
apy and often have better prognoses and clinical
outcomes than the basal and ERBB2-like sub-
types. The basal-like subtype is predominantly
ER-negative, progesterone receptor (PR)-negative
and ERBB2-negative (the triple negative) and as-
sociated with proliferative gene expression. The
ERBB2-like subtype is usually ER-negative and
has elevated expression of several genes of the
ERBB2 amplicon. The ERBB2-like and basal sub-
types often respond poorly to hormonal therapies
and have the worst prognoses.53,54 One funda-
mental question that needs to be addressed is
whether different subtypes of breast cancers are
derived from different origins, i.e. different breast
cancer stem cells. These different breast cancer
stem cells in turn may explain the different re-
sponse of each breast cancer subtype to the same
therapy. If this hypothesis holds true, identifica-
tion and characterization of each type of breast
cancer stem cell will become essential for design-
ing tailored treatments.
It has been reported that there is a putative
stem cell-like population in human breast can-
cers. These so-called breast cancer stem cells have
been isolated from human breast tumors or breast
cancer-derived pleural effusions using cell sur-
face markers in combination with flow cytome-
try. Al-Hajj et al defined these cells as CD44+,
CD24–/lowESA+ without specific lineage markers
(Lin−).40 Using NOD/SCID mice, they showed that
these cells have higher tumorigenic potential than
bulk tumor cells. When, CD44+CD24–/lowLin−
cells were isolated from tumors, these cells could
be transplanted to NOD/SCID mice and gener-
ate new tumors. This sequence could be serially
repeated several times, suggesting a robust self-
renewal capacity in the CD44+CD24–/lowLin− cells.
Another study used a low attachment in vitro cul-
ture system to show that single cell suspensions
of CD44+CD24–/lowLin− cells from human breast
cancers were able to proliferate extensively and
form clonal nonadherent mammospheres. These
mammospheres were more tumorigenic than the
established breast cancer-derived cell lines in-
cluding MCF-7 and B3R.55 Since then, there have
been many studies adapting these systems to iso-
late breast cancer stem cells from either human
breast tumors or human breast cancer cell lines
for further characterization such as analysis of
signal transduction pathways, gene expression,
and microRNAs to find factors important for the
self-renewal, tumorigenesis, and drug resistance
properties of breast cancer stem cells.56–62
Surface Markers Other Than 
CD44 and CD24
More recent studies have identified additional
markers useful in identifying breast cancer 
stem cells.59,63,64 At first, the strategy to identify
new markers was mainly based on the
CD44+CD24–/lowLin− criteria to isolate breast can-
cer stem cells. Using gene expression profiling of
CD44+ cells from breast carcinoma-derived pleu-
ral effusions, Shipitsin et al identified a CD44+
cell-specific gene, PROCR. PROCR encodes a cell
surface receptor and its expression is specific to
CD44+ epithelial cells.59 PROCR is also a known
marker of hematopoietic, neural, and embryonic
stem cells.65 Shipitsin et al used PROCR to iso-
late CD44+/PROCR+ cells from primary invasive
breast tumors and found that CD44+ and
PROCR+ cells were similar to each other and
were enriched with genes involved in cell motil-
ity, chemotaxis, hemostasis, and angiogenesis.
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These cells also expressed many stem cell specific
genes.59
Using flow cytometry, another study identified
an additional marker, CD133, for breast cancer
stem cells isolated from cell lines generated from
Brca1-exon11/p53+/– mouse mammary tumors.64
CD133 is a known marker of cancer stem cells in
several organs including brain, blood, liver and
prostate.41,42,66,67 Interestingly, they found that
the CD133+ stem cell-like population did not
overlap with the CD44+/CD24− population and
that both populations had a similar capacity for
self-renewal and could reconstitute cell fractions
found in the respective parental cells.64 This
finding suggests that there might be different
kinds of breast cancer stem cell subpopulations
that express surface markers other than CD44.
The CD133+ findings, along with the com-
plex, multistep method needed to isolate CD44+/
CD24−/Lin− cells suggests that using CD44+/
CD24−/Lin− as the only criteria to isolate breast
cancer stem cells may limit our ability to evaluate
other types of breast cancer stem cells that may
be more prominent in different types of breast
cancer. To overcome this limitation, other work-
ers have used in vitro and in vivo systems to show
that aldehyde dehydrogenase activity (ALDH)
was increased in a subpopulation of both nor-
mal and cancerous human mammary epithelial
cells that exhibit stem/progenitor cell properties.
In breast cancer, this subpopulation is tumori-
genic, capable of self-renewal, and able to gener-
ate tumors that have the heterogeneity of the
parental tumor.63 In this work, they showed that
there was only a small proportion of the CD44+/
CD24−/Lin− cells that overlapped with ALDH+
cells. However, all of the ALDH+ cells were able to
form tumors in NOD/SCID mice. The subpopu-
lation of cells that were both ALDH+ and CD44+/
CD24−/Lin− could generate tumors in vivo with
faster speed and larger size. In contrast, the
CD44+/CD24−/Lin− cells that were not ALDH+
could not form tumors in vivo. The ALDH finding
not only simplifies the process of isolating can-
cer stem cells but also opens up a new way to en-
rich cancer stem cells from breast tissues. It also
suggests that CD44+/CD24−/Lin−, previously the
defining characteristic of breast cancer stem cells,
is in fact just one subtype of breast cancer stem
cell. The implication that there might be various
subtypes of breast cancer stem cells is generally
similar to the well established hematopoietic
cancer stem cell system (Figure 1).
As described previously, there is only one
type of hematopoietic stem cell that can differen-
tiate into multipotent progenitors. Depending
on when the transformation events occur and
when the mutation phenotypes appear, different
types of leukemia may arise. In the breast, the sit-
uation is more complex because the normal stem
cell hierarchy is not yet fully understood. Using
in vitro assays, multi-parameter cell sorting and
functional characterization, the existence of lu-
minal epithelial and myoepithelial lineages have
been identified.38 However, whether there are dif-
ferent types of mammary stem cells and how the
mammary stem cells differentiate into lineage-
restricted progenitors have not yet been eluci-
dated. In terms of breast cancers, there are at
least five subtypes with distinct molecular profil-
ing and different responses to hormonal thera-
pies. These differences imply that there might be
different types of mammary stem cells, which in
turn give rise to different types of breast cancer
stem cells upon transformation. Moreover, cur-
rent reports using surface markers such as CD44,
CD24, CD133 and ALDH to identify stem cell
populations in breast cancers further suggest that
there might be different subtypes of breast cancer
stem cells in each type of breast cancer. Although
still uncertain, it is also possible that the progen-
itors derived from breast cancer stem cells, like the
hematopoietic system, may acquire self-renewal
ability and become tumorigenic through addi-
tional mutations or epigenetic events.
Using Breast Cancer Cell Lines as
Surrogates for Cancer Stem Cells
Clinical breast cancer specimens suitable for
stem cell isolation and analyses are difficult to
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obtain. Specimens obtained from patients after
chemotherapy are even more rare. Due to this
difficulty, many established human breast cancer
cell lines have been used as surrogates for human
breast cancer specimens in studies of gene ex-
pression profiling, signal transduction, and the
mechanisms of drug resistance in breast cancer
stem cells.58,61,62,68–74 Utilizing Hoechst 33342
W.W. Hwang-Verslues, et al
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Figure 1. Hierarchy of stem cells. Stem cells of all types can undergo asymmetric cell divisions that generate two daughter
cells: one is identical to the original cell and carries on the stem cell function (self-renewal) and the other, referred to as
a progenitor cell, is committed to differentiation. The progenitor cell gives rise to precursor cells which finally give rise to
terminally differentiated mature cells. (A) Hierarchy of normal hematopoietic stem cells: the self-renewal process is tightly
regulated and the numbers of stem cells and progenitor cells produced are constant and tightly controlled. However, the
high level of self-renewal and longevity of these cells make them good targets for transformation. (B) Hierarchy of
hematopoietic cancer stem cells. During and after transformation, the mechanisms that control self-renewal become
deregulated. This may occur in stem cells and lead to an increase in stem cell number and production of cancer cells (B-I).
Alternatively, transformation may occur in progenitor cells. These progenitor cells would then gain self-renewal ability
and proliferate uncontrollably, also leading to cancer cell production (B-II). Depending on when the transformation
events occur (scenario B-I or B-II), different leukemias would arise. (C) Hierarchy of breast cancer stem cells. In breast
cancers, less is known about what types of transformation occur, although it is again likely that either stem cells or pro-
genitor cells can be transformed. Different types of breast cancer stem cells may give rise to different types of breast can-
cer cells which in turn may generate different subtypes of breast cancers (C-I). It is also possible that the progenitors
derived from breast stem cells, like the hematopoietic system, may acquire self-renewal ability and become tumorigenic
through additional mutations or epigenetic events (C-II). The triangle represents transformation events.
dye efflux assays, flow cytometry for isolation of
CD44+/CD24−/Lin− cells, or BrdU label retention
assays, subpopulations that have stem cell prop-
erties were identified from human breast cancer
cell lines such as MCF-7 and SK-BR-3. The stem
cell-like populations isolated from these cell lines
were shown to be resistant to chemotherapy
drugs, such as epirubicin,61 and to irradiation
treatment.71
Utilizing the characteristic that stem cells are
more resistant to chemotherapy drugs than non-
stem cells, Yu et al developed a system to eluci-
date whether miRNAs are involved in regulating
the self-renewal capacity tumor initiation ability
of breast cancer stem cells. Yu et al generated a
highly malignant cell line, SK-3rd, by first inject-
ing SK-BR-3 cells into the mammary fat pad of
NOD/SCID mice treated with epirubicin, and
then consecutively passaging the breast cancer
cells from the tumors in NOD/SCID mice. They
compared miRNA expression in SK-BR-3 and SK-
3rd cells as well as their CD44+/CD24− status with
that of cancer cells from breast tumor specimens.
Their analyses showed that epirubicin treatment
enriched stem cell-like populations. Moreover,
the miRNA expression results demonstrated that
let-7 miRNA increased in SK-3rd and CD44+/
CD24− cells, which led to a strong reduction of
let-7 expression. The opposite result was ob-
served when cells were induced to differentiate.
Utilizing in vitro and in vivo assays such as overex-
pression and knockdown of let-7, they demon-
strated a regulatory pathway by which let-7 acted
as a tumor suppressor to inhibit the self-renewal
capacity of cancer stem cells by reducing H-Ras
protein levels; let-7 also enhanced differentiation
by decreasing HMGA2 protein levels.61
The CD44+/CD24− criteria can only be used
in a few cell lines such as MCF7 and SK-BR-3. In
other cell lines, the prevalence of CD44+/CD24−
cells within the breast cancer cell line does not
correlate with tumorigenicity69 (and our unpub-
lished data). Fillmore and Kuperwasser examined
CD44 and CD24 in eight human breast cancer
cell lines using flow cytometry. They found that
rather than tumorigenicity, the percentage of
CD44+/CD24− cells consistently correlates with 
a basal cellular phenotype. By adding one more
parameter, ESA, they observed an enrichment 
of the stem cell-like population in the CD44+/
CD24−/ESA+ fraction. This subpopulation can
self-renew and reconstitute the parental cell line
in every cell line tested.69 This finding, along with
the other studies mentioned above,63,64 empha-
sizes the fact that new surface markers are needed
for breast cancer stem cell isolation and identi-
fication and that use of additional markers will
allow the identification of different subpopula-
tions of breast cancer stem cells that vary in their
prevalence in different breast cancers.
Tumor Suppressors Rb, BRCA1, BRCA2
and p53 in Breast Cancer
It is well recognized that many tumor suppressor
genes play an important role in breast cancer 
initiation and progression. The retinoblastoma
tumor suppressor (RB) is the first tumor suppres-
sor shown to be altered in breast cancer.75 Loss
of RB function could lead to aggressive prolif-
eration and resistance to anti-estrogen hormonal
therapy.76 Besides RB, BRCA1 and BRCA2 are
two well-characterized breast cancer susceptibil-
ity genes. Mutations in BRCA1 and BRCA2 are
associated with familial breast cancer syndrome.
In addition, germline mutations of p53 have
been linked to the Li-Fraumeni syndrome. These
carriers are at high risk of developing early onset
breast cancer.77,78
What is the Role of Tumor Suppressors
in Breast Cancer Stem Cells?
Normal stem cells have a longer life span than
differentiated cells. Their longevity makes them 
a target for accumulating mutations. Thus, it is
reasonable to assume that cancer stem cells arise
from normal stem cells. The major difference be-
tween normal stem cells and cancer stem cells is
the deregulation of cell proliferation. The majority
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of known tumor suppressors, including RB,
BRCA1, BRCA2 and p53, are key proteins in cell
cycle control, DNA damage repair including ho-
mologous recombination and non-homologous
end joining, and regulation of apoptosis. Thus, it
is fairly likely that the first hit that transforms
normal stem cells to cancer stem cells is the mu-
tation of one of these tumor suppressor genes
(Figure 2). Although there are many studies that
have described the roles of developmental path-
ways such as the proto-oncogene NOTCH,
Hedgehog, and Wnt in stem and progenitor cell
self-renewal and differentiation,56,57,79,80 there are
only a few studies that have investigated the roles
of tumor suppressors involved in the regulation
of stem cell fate. In particular, the role of the
major tumor suppressors RB, BRCA1, BRCA2, and
p53 in cancer stem cell transformation deserve
further consideration.
RB
The RB gene was the first identified tumor suppres-
sor gene. The tumor suppression function of RB
was demonstrated by reintroducing a wild-type RB
allele into RB-deficient retinoblastoma cells and
other human tumors with subsequent repression
W.W. Hwang-Verslues, et al
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Figure 2. Roles of tumor suppressors in the transformation of breast cancer stem cells. Tumor suppressors, including Rb,
BRCA1, BRCA2 and p53, are key proteins in cell cycle control, DNA damage repair, regulation of apoptosis, and mainte-
nance of differentiation phenotypes. Thus, it is likely that these tumor suppressors play roles in the regulation of stem cell
proliferation. Loss of these tumor suppressors, therefore, could be the first step that transforms normal stem cells to 
cancer stem cells. Loss of functional tumor suppressors could also occur in multipotent progenitors, which could allow
the progenitors to regain self-renewal ability and lead to tumorigenesis.
of tumorigenesis in nude mice.81,82 Biochemical
and cell biological studies have shown that RB
functions as a transcriptional modulator which
controls the expression of genes essential for cell
cycle progression.83–85 It has also been shown to
play a critical role in the maintenance of chromo-
some stability.86,87 Moreover, in both mammals
and nematodes, RB has been shown to control
cell lineage specification and differentiation.88
In breast cancer, it has been reported that
about 20–35% of primary breast tumors have
lost RB expression, and 7–37% of breast tumors
contain loss of heterozygosity or other alter-
ations of the RB locus.89–92 In breast cancer cell
lines, RB deficiency could promote cell prolif-
eration and enhance tumorigenic proliferation
in mouse xenografts.93 In primary breast cancer
specimens, tumors with a deficiency of RB are
generally more proliferative and RB deficiency
correlates with poor disease outcomes.94,95 Upon
stimulation by mitogenic signals such as estrogen,
a series of transcriptional regulation and signal
transduction events can occur and lead to phos-
phorylation and inactivation of RB, and there-
fore promote cell cycle progression.85 One of the
mechanisms is the activation of the ER. Activated
ER is able to initiate expression of cyclin D196,97
and then increase the formation of the cyclin D1/
CDK4 complex which in turn inactivates RB by
phosphorylation and allows cell cycle progression.
In breast cancer therapies, anti-estrogen treatments
that antagonize ER function lead to inhibition of
cyclin D1 expression, and therefore prevent CDK
activation and RB phosphorylation to inhibit cell
cycle progression.98,99 It has recently been dem-
onstrated that RNA interference-mediated RB de-
ficiency in human breast cancer cell lines leads
to cell cycle progression during estrogen depriva-
tion and estrogen-antagonist treatment.93 These
cells also become tamoxifen resistant, which is
one of the major problems in clinical hormonal
treatment of breast cancer. However, the impact
of RB on patient response to tamoxifen or other
hormonal regimens has not been fully investi-
gated. Nevertheless, the fact that RB-deficient
cells are more proliferative, tumorigenic and can
be resistant to hormonal therapies favors the hy-
pothesis that mutation in RB may contribute to
the transforming process by which cancer stem
cells arise from normal stem cells.
BRCA1
Another tumor suppressor gene, BRCA1, is asso-
ciated with familial breast cancer and shares sim-
ilar properties with RB. One of the functions of
BRCA1 is cell cycle control.100 Moreover, it has
been shown that growth arrest induced by over-
expression of BRCA1 is RB-dependent.101 BRCA1
interacts with many proteins involved in different
cellular functions. These proteins include BRCA2,
p53, RAD51 and other proteins involved in the
cell cycle G2-M check point. BRCA1 also interacts
with DNA damage response proteins, particularly
those involved in homologous recombination
(HR) and non-homologous end-joining (NHEJ),
as well as a number of transcriptional activators
and repressors. In response to DNA damage,
BRCA1 is phosphorylated by ataxia telangiectasia
mutated (ATM) and checkpoint kinase 2 (CHK2)
proteins. Cells without functional BRCA1 do not
arrest in the cell cycle G2 phase in response to
DNA damage. These cells are also deficient in
transcription-coupled repair. In response to DNA
double strand breaks, BRCA1 may recruit the
MRE11-RAD50-NBS1 complex or RAD51 to the
break sites and initiate the HR or NHEJ repair
pathways.102,103 Moreover, the amino-terminal
RING domain of BRCA1 allows it to regulate
ubiquitination of the ER and PR.104
Approximately 5–10% of all breast cancers
are familial breast cancer. BRCA1 mutations ac-
count for about half of the cases. In sporadic
breast cancers, BRCA1 mutations are rare; how-
ever, BRCA1 expression is often reduced or ab-
sent due to hypermethylation of its promoter.105
BRCA1-associated breast cancers are often high-
grade ER/PR/Her2 triple negative basal cell-like
tumors106 with p53 and PTEN mutations.107 Using
mouse models and human breast cancer cell
lines, BRCA1 has been suggested to play a role in
mammary gland development and differentia-
tion.108–110 Using in vitro systems and a humanized
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NOD/SCID mouse model, Liu et al showed that
BRCA1 expression is required for the differentia-
tion of ER-negative stem or progenitor cells to
ER-positive luminal cells. BRCA1 knockdown re-
sulted in increased expression of ALDH1, a stem
cell marker, and a decrease in luminal epithelial
markers and ER in primary breast epithelial cells.111
This finding suggests that BRCA1-mutated breast
cells may behave more similarly to stem or progen-
itor cells. However, these cells may also accumu-
late mutations since BRCA1 plays an important
role in DNA repair and genome maintenance.
Thus, mutations in BRCA1 might be the first step
in transforming normal stem cells to cancer stem
cells in those familial cases.
ER/PR/Her2 triple negative basal cell-like tu-
mors often respond very well to chemotherapy
in the beginning. However, tumors that do not
respond well to the treatment can relapse and
progress rapidly. Several new therapeutic strate-
gies have been tested and proposed. Promising
treatments such as poly(ADP-ribose) polymerase
(PARP1) inhibitors utilize the fact that BRCA1 has
roles in DNA repair.112 It has also been reported
that cell lines with BRCA1 mutations are sensitive
to cisplatin but not to doxorubicin.113,114 Using
Brca1/p53-deficient mice, anti-progesterone treat-
ment was proposed for breast cancer prevention
in individuals with inherited BRCA1 mutations.115
Although it has been reported that cell lines
with BRCA1 mutations are sensitive to cisplatin
but not to doxorubicin,113,114 other studies have
recently shown that Brca1/p53-mutated tumors
can be resistant to cisplatin treatment.116 A con-
ditional Brca1/p53 knockout mouse model was
used to show that Brca1/p53-mutated spontane-
ous tumors respond better to cisplatin than doxo-
rubicin treatment; however, tumor recurrence
does occur. Using CD29 and CD24 surface mark-
ers, Shafee et al demonstrated that a subpopula-
tion of cancer stem cells in the Brca1/p53-mutated
tumors were cisplatin resistant.116
BRCA2
Similar to BRCA1, BRCA2 is involved in repair of
DNA damage and maintenance of chromosome
integrity. In normal cells, BRCA2 interacts with pro-
teins such as RAD51 to repair DNA strand breaks.
BRCA2-deficient mouse embryo fibroblasts de-
velop gross chromosomal abnormalities within
a few cell divisions. The formation of spontane-
ous DNA double stranded breaks, tri-radials and
quadric-radials in BRCA2-deficient cells strongly
suggests a role for BRCA2 in DNA double stranded
break repair, chromosomal segregation and main-
tenance of genomic stability.117–120
There are many mutations identified in the
BRCA2 gene and all of these mutations are asso-
ciated with breast cancer susceptibility.121 Many
BRCA2 mutations result from insertion or deletion
of a small number of nucleotides. These frame
shift mutations lead to a nonfunctional BRCA2
protein. Mono-allelic mutations in the BRCA2
gene cause susceptibility to breast and other can-
cers, whereas bi-allelic mutations cause a rare au-
tosomal recessive cancer susceptibility syndrome,
Fanconi anemia.122 Although BRCA2 shares sev-
eral similar functions in DNA damage repair and
maintaining chromosome stability with BRCA1,
whether or not BRCA2 is involved in stem cell
transformation remains unknown. Nevertheless,
mutated BRCA2 might play a role in the transfor-
mation of breast cancer stem cells since it makes
cells more susceptible to accumulation of DNA
damage.
Recently, the mechanism by which BRCA2-
mutated tumors are resistant to platinum-based
treatments and PARP inhibitor has been eluci-
dated.123,124 Cisplatin and PARP inhibitor resistant
clones were derived from breast and pancreatic
cancer cell lines with BRCA2 mutations, and
BRCA2 function and sequence analyzed. They
found that drug resistance in these cell lines can
be mediated by secondary intragenic deletions in
the BRCA2 gene to restore the wild-type BRCA2
reading frame and rescue the deficiency in homol-
ogous recombination. Similar results were found
in cisplatin and carboplatin-resistant ovarian tu-
mors. Since most of the deletions in BRCA2 were
associated with small tracts of homology, the au-
thors speculated that the intragenic deletions may
arise from error-prone repair caused by BRCA2
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deficiency.123 Although these two studies did not
investigate whether cancer stem cells may con-
tribute to drug resistance, further investigation
should be done to examine whether the error-
prone repair mechanism is somehow more active
in cancer stem cells and leads to the restoration of
BRCA2 function in response to drug treatments.
p53
The tumor suppressor p53 can activate or repress
a large number of target genes involved in differ-
ent functions including cell cycle regulation, apo-
ptosis induction, DNA repair, anti-angiogenesis
and genome maintenance.125–128 p53 is one of the
most commonly mutated genes in human cancer
and has a key role in repressing cell growth and
inducing apoptosis in response to DNA damage,
hypoxia and other stress signals.127,129 The most
frequent p53 mutated sites reside in the DNA-
binding domain.130 When mutant p53 is over-
expressed, a dominant-negative effect can occur
which leads to loss of function of wild-type p53.131
Germline mutations in p53 have been shown to
cause the rare familial autosomal Li-Fraumeni
syndrome, which is characterized by a high inci-
dence of many cancers including early onset
breast cancer. This type of early onset breast can-
cer is only a small proportion (< 1%) of all breast
cancer cases.77 As described previously, BRCA1
has been implicated in DNA damage repair, cell
cycle checkpoint regulation, and transcriptional
regulation,102,103 functions that are highly over-
lapped with p53 functions. The mechanisms of
both proteins in DNA double-stranded break 
repair also overlap. It has been proposed that
BRCA1 might function as a scaffold for facilitat-
ing the ATM and ATR-dependent phosphorylation
of p53.132,133 Interestingly, human breast cancers
with germline mutations in BRCA1 often have p53
mutations.134 Somatic p53 mutations are more
common and occur in about 30–40% of high-
grade ductal carcinomas in situ. This observation
suggests an important role of p53 alterations
early in breast carcinogenesis.135 In addition, p53
mutations occur more frequently in the basal/
myoepithelial type and ERBB2 (Her2) classes than
luminal-type breast cancer.50 Although p53 has
recently been implicated in the negative regula-
tion of self-renewal in cancer stem cells,136 there
is no solid evidence suggesting that p53 is in-
volved in determination of stem cell fate. If p53,
at a basal level, plays a critical role in this aspect,
it might involve an as-yet-unknown p53 function.
Thus, due to its role in maintaining genome sta-
bility and proper cell cycle progression, the pos-
sibility that mutated p53 in normal stem cells
might result in higher susceptibility to transfor-
mation needs to be further investigated.
Perspectives
There is increasing evidence suggesting the exis-
tence of breast cancer stem cells. One of the im-
portant questions needing to be addressed is
whether there is a uniform population or hetero-
geneous populations of breast cancer stem cells
in a single tumor. Most current studies have em-
phasized the identification of cancer stem cell
subpopulations from breast tumors using cell
surface markers. CD44 and CD24 are the markers
most frequently used for this purpose. However,
more recent data suggest that the newly identi-
fied marker ALDH1 could be more effective in
identifying the most tumorigenic breast cancer
stem cells. Since the ALDH1+ cells, but not the
CD44+/CD24−/ALDH1− cells, are able to gener-
ate tumors in NOD/SCID mice, use of CD44+/
CD24− can only isolate a subset of breast cancer
stem cells. Moreover, it has been reported that
use of the surface marker CD133 can isolate a
group of breast cancer stem cells that does not
overlap with CD44+/CD24− cells. Taken together,
these data suggest the existence of different sub-
types of cancer stem cells in breast tumors. More
studies are required to characterize each subtype
of cancer stem cells, and whether they exist to-
gether in the same tumors, or are differentially
present in different types of breast cancers. The
extent to which different types of breast cancers
have distinct stem cell compositions could shed
light on why the same treatments lead to different
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clinical outcomes for different types of breast
cancer. Verification of this hypothesis could also
shed light on the clinical observation that breast
cancer patients can respond differently to con-
ventional chemotherapies, and why some develop
refractory tumors.
The major difference between normal stem
cells and cancer stem cells is the deregulated cell
proliferation in the latter. One fundamental ques-
tion is what the first step is that initiates the trans-
formation from normal stem cells to cancer stem
cells. Tumor suppressors such as RB, BRCA1,
BRCA2, and p53 play significant roles in control
of proper cell cycle progression and maintenance
of genome integrity. Furthermore, the deregula-
tion of these tumor suppressor genes is highly
associated with familial breast cancer and resis-
tance to current therapies. Therefore, it is reason-
able to hypothesize that mutations in these genes
may start the transformation process which con-
verts normal stem cells to cancer stem cells. Dif-
ferent mutations in different tumor suppressors
may result in different types of cancer stem cells,
thereby offering an explanation for the widely-
differing responses to chemotherapy in different
types of breast cancer.
We are just beginning to find the range of
cancer stem cells found in breast tumors, and
further cancer stem cell isolation using new
markers is needed. Identification and characteri-
zation of different types of cancer stem cells, as
well as elucidation of the mechanisms underly-
ing the conversion of normal stem cells, or pro-
genitor cells, to cancer stem cells, could provide
opportunities to further define the most critical
differences between these cancer stem cells and
normal mammary cells. This would in turn allow
more focused therapeutic study of a small set of
targets that are of greatest clinical relevance.
References
1. Potten CS, Loeffler M. Stem cells: attributes, cycles, spi-
rals, pitfalls and uncertainties. Lessons for and from the
crypt. Development 1990;110:1001–20.
2. Clarke MF, Fuller M. Stem cells and cancer: two faces of
eve. Cell 2006;124:1111–5.
3. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer,
and cancer stem cells. Nature 2001;414:105–11.
4. Weissman IL, Anderson DJ, Gage F. Stem and progenitor
cells: origins, phenotypes, lineage commitments, and
transdifferentiations. Annu Rev Cell Dev Bio 2001;17:
387–403.
5. Cheng T, Rodrigues N, Dombkowski D, et al. Stem cell 
repopulation efficiency but not pool size is governed by
p27(kip1). Nat Med 2000;6:1235–40.
6. Cheng T, Rodrigues N, Shen H, et al. Hematopoietic stem
cell quiescence maintained by p21cip1/waf1. Science
2000;287:1804–8.
7. Morrison SJ, Qian D, Jerabek L, et al. A genetic determinant
that specifically regulates the frequency of hematopoietic
stem cells. J Immunol 2002;168:635–42.
8. Passegue E, Wagers AJ, Giuriato S, et al. Global analysis of
proliferation and cell cycle gene expression in the regula-
tion of hematopoietic stem and progenitor cell fates. J Exp
Med 2005;202:1599–611.
9. Forsberg EC, Prohaska SS, Katzman S, et al. Differential
expression of novel potential regulators in hematopoietic
stem cells. PLoS Genet 2005;1:e28.
10. Spradling A, Drummond-Barbosa D, Kai T. Stem cells find
their niche. Nature 2001;414:98–104.
11. Akala OO, Park IK, Qian D, et al. Long-term haemato-
poietic reconstitution by Trp53-/-p16Ink4a-/-p19Arf-/-
multipotent progenitors. Nature 2008;453:228–32.
12. Tan BT, Park CY, Ailles LE, et al. The cancer stem cell
hypothesis: a work in progress. Lab Invest 2006;86:
1203–7.
13. George AA, Franklin J, Kerkof K, et al. Detection of
leukemic cells in the CD34(+)CD38(-) bone marrow pro-
genitor population in children with acute lymphoblastic
leukemia. Blood 2001;97:3925–30.
14. Mauro MJ, Druker BJ. Chronic myelogenous leukemia.
Curr Opin Oncol 2001;13:3–7.
15. Miyamoto T, Weissman IL, Akashi K. AML1/ETO-expressing
nonleukemic stem cells in acute myelogenous leukemia
with 8;21 chromosomal translocation. Proc Natl Acad Sci
USA 2000;97:7521–6.
16. Lagasse E, Weissman IL. bcl-2 inhibits apoptosis of neu-
trophils but not their engulfment by macrophages. J Exp
Med 1994;179:1047–52.
17. Traver D, Akashi K, Weissman IL, et al. Mice defective in
two apoptosis pathways in the myeloid lineage develop
acute myeloblastic leukemia. Immunity 1998;9:47–57.
18. Tsai YC, Lu Y, Nichols PW, et al. Contiguous patches of
normal human mammary epithelium derived from a single
stem cell: implications for breast carcinogenesis. Cancer
Res 1996;56:402–4.
19. Kordon EC, Smith GH. An entire functional mammary
gland may comprise the progeny from a single cell.
Development 1998;125:1921–30.
W.W. Hwang-Verslues, et al
762 J Formos Med Assoc | 2008 • Vol 107 • No 10
20. Shackleton M, Vaillant F, Simpson KJ, et al. Generation of
a functional mammary gland from a single stem cell.
Nature 2006;439:84–8.
21. Stingl J, Eirew P, Ricketson I, et al. Purification and unique
properties of mammary epithelial stem cells. Nature
2006;439:993–7.
22. Kenney NJ, Smith GH, Lawrence E, et al. Identification of
stem cell units in the terminal end bud and duct of the
mouse mammary gland. J Biomed Biotechnol 2001;1:
133–43.
23. Smith GH. Label-retaining epithelial cells in mouse mam-
mary gland divide asymmetrically and retain their template
DNA strands. Development 2005;132:681–7.
24. Hirschmann-Jax C, Foster AE, Wulf GG, et al. A distinct “side
population” of cells with high drug efflux capacity in human
tumor cells. Proc Natl Acad Sci USA 2004;101:14228–33.
25. Campos LS. Neurospheres: insights into neural stem cell
biology. J Neurosci Res 2004;78:761–9.
26. Kiel MJ, He S, Ashkenazi R, et al. Haematopoietic stem
cells do not asymmetrically segregate chromosomes or 
retain BrdU. Nature 2007;449:238–42.
27. Morrison SJ, Spradling AC. Stem cells and niches: mecha-
nisms that promote stem cell maintenance throughout
life. Cell 2008;132:598–611.
28. Alvi AJ, Clayton H, Joshi C, et al. Functional and molecular
characterisation of mammary side population cells. Breast
Cancer Res 2003;5:R1–8.
29. Clarke RB, Anderson E, Howell A, et al. Regulation of
human breast epithelial stem cells. Cell Prolif 2003;
36(Suppl 1):45–58.
30. Clarke RB, Spence K, Anderson E, et al. A putative human
breast stem cell population is enriched for steroid receptor-
positive cells. Dev Biol 2005;277:443–56.
31. Clayton H, Titley I, Vivanco M. Growth and differentiation
of progenitor/stem cells derived from the human mammary
gland. Exp Cell Res 2004;297:444–60.
32. Dontu G, Abdallah WM, Foley JM, et al. In vitro propaga-
tion and transcriptional profiling of human mammary stem/
progenitor cells. Genes Dev 2003;17:1253–70.
33. Dontu G, Wicha MS. Survival of mammary stem cells in sus-
pension culture: implications for stem cell biology and neo-
plasia. J Mammary Gland Biol Neoplasia 2005;10:75–86.
34. Bocker W, Moll R, Poremba C, et al. Common adult stem
cells in the human breast give rise to glandular and 
myoepithelial cell lineages: a new cell biological concept.
Lab Invest 2002;82:737–46.
35. Gudjonsson T, Villadsen R, Nielsen HL, et al. Isolation, 
immortalization, and characterization of a human breast
epithelial cell line with stem cell properties. Genes Dev
2002;16:693–706.
36. Stingl J, Raouf A, Eirew P, et al. Deciphering the mammary
epithelial cell hierarchy. Cell Cycle 2006;5:1519–22.
37. Welm BE, Tepera SB, Venezia T, et al. Sca-1(pos) cells in
the mouse mammary gland represent an enriched pro-
genitor cell population. Dev Biol 2002;245:42–56.
38. Villadsen R, Fridriksdottir AJ, Ronnov-Jessen L, et al.
Evidence for a stem cell hierarchy in the adult human
breast. J Cell Biol 2007;177:87–101.
39. Bonnet D, Dick JE. Human acute myeloid leukemia is 
organized as a hierarchy that originates from a primitive
hematopoietic cell. Nat Med 1997;3:730–7.
40. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Pro-
spective identification of tumorigenic breast cancer cells.
Proc Natl Acad Sci USA 2003;100:3983–8.
41. Singh SK, Clarke ID, Hide T, et al. Cancer stem cells in
nervous system tumors. Oncogene 2004;23:7267–73.
42. Collins AT, Berry PA, Hyde C, et al. Prospective identifica-
tion of tumorigenic prostate cancer stem cells. Cancer Res
2005;65:10946–51.
43. Fang D, Nguyen TK, Leishear K, et al. A tumorigenic sub-
population with stem cell properties in melanomas.
Cancer Res 2005;65:9328–37.
44. O’Brien CA, Pollett A, Gallinger S, et al. A human colon
cancer cell capable of initiating tumour growth in immuno-
deficient mice. Nature 2007;445:106–10.
45. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification
and expansion of human colon-cancer-initiating cells.
Nature 2007;445:111–5.
46. Matsui W, Huff CA, Wang Q, et al. Characterization 
of clonogenic multiple myeloma cells. Blood 2004;103:
2332–6.
47. Li C, Heidt DG, Dalerba P, et al. Identification of pancre-
atic cancer stem cells. Cancer Res 2007;67:1030–7.
48. Kim CF, Jackson EL, Woolfenden AE, et al. Identification
of bronchioalveolar stem cells in normal lung and lung
cancer. Cell 2005;121:823–35.
49. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of
human breast tumours. Nature 2000;406:747–52.
50. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression
patterns of breast carcinomas distinguish tumor subclasses
with clinical implications. Proc Natl Acad Sci USA 2001;
98:10869–74.
51. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation
of breast tumor subtypes in independent gene expression
data sets. Proc Natl Acad Sci USA 2003;100:8418–23.
52. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer clas-
sification and prognosis based on gene expression profiles
from a population-based study. Proc Natl Acad Sci USA
2003;100:10393–8.
53. Stingl J, Caldas C. Molecular heterogeneity of breast carci-
nomas and the cancer stem cell hypothesis. Nat Rev
Cancer 2007;7:791–9.
54. Vargo-Gogola T, Rosen JM. Modelling breast cancer: one
size does not fit all. Nat Rev Cancer 2007;7:659–72.
55. Ponti D, Costa A, Zaffaroni N, et al. Isolation and in vitro
propagation of tumorigenic breast cancer cells with stem/
progenitor cell properties. Cancer Res 2005;65:5506–11.
56. Dontu G, Jackson KW, McNicholas E, et al. Role of Notch
signaling in cell-fate determination of human mammary
stem/progenitor cells. Breast Cancer Res 2004;6:R605–15.
Breast cancer stem cells and tumor suppressor genes
J Formos Med Assoc | 2008 • Vol 107 • No 10 763
57. Liu S, Dontu G, Mantle ID, et al. Hedgehog signaling 
and Bmi-1 regulate self-renewal of normal and malig-
nant human mammary stem cells. Cancer Res 2006;66:
6063–71.
58. Sansone P, Storci G, Giovannini C, et al. p66Shc/Notch-3
interplay controls self-renewal and hypoxia survival in
human stem/progenitor cells of the mammary gland ex-
panded in vitro as mammospheres. Stem Cells 2007;25:
807–15.
59. Shipitsin M, Campbell LL, Argani P, et al. Molecular def-
inition of breast tumor heterogeneity. Cancer Cell 2007;
11:259–73.
60. Storci G, Sansone P, Trere D, et al. The basal-like breast
carcinoma phenotype is regulated by SLUG gene ex-
pression. J Pathol 2008;214:25–37.
61. Yu F, Yao H, Zhu P, et al. let-7 regulates self renewal 
and tumorigenicity of breast cancer cells. Cell 2007;131:
1109–23.
62. Zhou J, Wulfkuhle J, Zhang H, et al. Activation of the
PTEN/mTOR/STAT3 pathway in breast cancer stem-like
cells is required for viability and maintenance. Proc Natl
Acad Sci USA 2007;104:16158–63.
63. Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is
a marker of normal and malignant human mammary
stem cells and a predictor of poor clinical outcome. 
Cell Stem Cell 2007;1:555–67.
64. Wright MH, Calcagno AM, Salcido CD, et al. Brca1 breast
tumors contain distinct CD44+/CD24− and CD133+
cells with cancer stem cell characteristics. Breast Cancer
Res 2008;10:R10.
65. Ivanova NB, Dimos JT, Schaniel C, et al. A stem cell 
molecular signature. Science 2002;298:601–4.
66. Vercauteren SM, Sutherland HJ. CD133 (AC133) expres-
sion on AML cells and progenitors. Cytotherapy 2001;
3:449–59.
67. Yin S, Li J, Hu C, et al. CD133 positive hepatocellular
carcinoma cells possess high capacity for tumorigenicity.
Int J Cancer 2007;120:1444–50.
68. Cariati M, Naderi A, Brown JP, et al. Alpha-6 integrin is
necessary for the tumourigenicity of a stem cell-like sub-
population within the MCF7 breast cancer cell line. Int J
Cancer 2008;122:298–304.
69. Fillmore CM, Kuperwasser C. Human breast cancer cell
lines contain stem-like cells that self-renew, give rise to
phenotypically diverse progeny and survive chemother-
apy. Breast Cancer Res 2008;10:R25.
70. Hughes L, Malone C, Chumsri S, et al. Characterisation
of breast cancer cell lines and establishment of a novel
isogenic subclone to study migration, invasion and 
tumourigenicity. Clin Exp Metastasis 2008;25:549–57.
71. Phillips TM, McBride WH, Pajonk F. The response 
of CD24(-/low)/CD44 + breast cancer-initiating cells to
radiation. J Natl Cancer Inst 2006;98:1777–85.
72. Sheridan C, Kishimoto H, Fuchs RK, et al. CD44+/
CD24− breast cancer cells exhibit enhanced invasive
properties: an early step necessary for metastasis.
Breast Cancer Res 2006;8:R59.
73. Tang B, Yoo N, Vu M, et al. Transforming growth factor-
beta can suppress tumorigenesis through effects on the
putative cancer stem or early progenitor cell and com-
mitted progeny in a breast cancer xenograft model.
Cancer Res 2007;67:8643–52.
74. Woodward WA, Chen MS, Behbod F, et al. WNT/beta-
catenin mediates radiation resistance of mouse mam-
mary progenitor cells. Proc Natl Acad Sci USA 2007;
104:618–23.
75. Lee WH. The molecular basis of cancer suppression by
the retinoblastoma gene. Princess Takamatsu Symp
1989;20:159–70.
76. Bosco EE, Knudsen ES. RB in breast cancer: at the cross-
roads of tumorigenesis and treatment. Cell Cycle 2007;
6:667–71.
77. Antoniou AC, Easton DF. Models of genetic susceptibility
to breast cancer. Oncogene 2006;25:5898–905.
78. Walsh T, King MC. Ten genes for inherited breast 
cancer. Cancer Cell 2007;11:103–5.
79. Reya T, Clevers H. Wnt signalling in stem cells and 
cancer. Nature 2005;434:843–50.
80. Reya T, Duncan AW, Ailles L, et al. A role for Wnt sig-
nalling in self-renewal of haematopoietic stem cells.
Nature 2003;423:409–14.
81. Huang HJ, Yee JK, Shew JY, et al. Suppression of the
neoplastic phenotype by replacement of the RB gene in
human cancer cells. Science 1988;242:1563–6.
82. Riley DJ, Lee EY, Lee WH. The retinoblastoma protein:
more than a tumor suppressor. Annu Rev Cell Biol 1994;
10:1–29.
83. Frolov MV, Dyson NJ. Molecular mechanisms of E2F-
dependent activation and pRB-mediated repression. 
J Cell Sci 2004;117:2173–81.
84. Jackson MW, Agarwal MK, Yang J, et al. p130/p107/
p105Rb-dependent transcriptional repression during
DNA-damage-induced cell-cycle exit at G2. J Cell Sci
2005;118:1821–32.
85. Zheng L, Lee WH. The retinoblastoma gene: a proto-
typic and multifunctional tumor suppressor. Exp Cell Res
2001;264:2–18.
86. van Deursen JM. Rb loss causes cancer by driving mito-
sis mad. Cancer Cell 2007;11:1–3.
87. Zheng L, Flesken-Nikitin A, Chen PL, et al. Deficiency 
of retinoblastoma gene in mouse embryonic stem cells
leads to genetic instability. Cancer Res 2002;62:
2498–502.
88. Skapek SX, Pan YR, Lee EY. Regulation of cell lineage
specification by the retinoblastoma tumor suppressor.
Oncogene 2006;25:5268–76.
89. Borg A, Zhang QX, Alm P, et al. The retinoblastoma 
gene in breast cancer: allele loss is not correlated with
loss of gene protein expression. Cancer Res 1992;52:
2991–4.
W.W. Hwang-Verslues, et al
764 J Formos Med Assoc | 2008 • Vol 107 • No 10
90. Chano T, Kontani K, Teramoto K, et al. Truncating muta-
tions of RB1CC1 in human breast cancer. Nat Genet
2002;31:285–8.
91. Oesterreich S, Fuqua SA. Tumor suppressor genes in
breast cancer. Endocr Relat Cancer 1999;6:405–19.
92. Pietilainen T, Lipponen P, Aaltomaa S, et al. Expression 
of retinoblastoma gene protein (Rb) in breast cancer as
related to established prognostic factors and survival. 
Eur J Cancer 1995;31A:329–33.
93. Bosco EE, Wang Y, Xu H, et al. The retinoblastoma
tumor suppressor modifies the therapeutic response of
breast cancer. J Clin Invest 2007;117:218–28.
94. Jares P, Rey MJ, Fernandez PL, et al. Cyclin D1 and
retinoblastoma gene expression in human breast carci-
noma: correlation with tumour proliferation and oestro-
gen receptor status. J Pathol 1997;182:160–6.
95. Nielsen NH, Loden M, Cajander J, et al. G1-S transition
defects occur in most breast cancers and predict out-
come. Breast Cancer Res Treat 1999;56:105–12.
96. Eeckhoute J, Carroll JS, Geistlinger TR, et al. A cell-type-
specific transcriptional network required for estrogen
regulation of cyclin D1 and cell cycle progression in
breast cancer. Genes Dev 2006;20:2513–26.
97. Foster JS, Henley DC, Ahamed S, et al. Estrogens and
cell-cycle regulation in breast cancer. Trends Endocrinol
Metab 2001;12:320–7.
98. Osborne CK, Boldt DH, Clark GM, et al. Effects of 
tamoxifen on human breast cancer cell cycle kinetics:
accumulation of cells in early G1 phase. Cancer Res
1983;43:3583–5.
99. Watts CK, Brady A, Sarcevic B, et al. Antiestrogen inhibi-
tion of cell cycle progression in breast cancer cells in 
associated with inhibition of cyclin-dependent kinase
activity and decreased retinoblastoma protein phospho-
rylation. Mol Endocrinol 1995;9:1804–13.
100. Mullan PB, Quinn JE, Harkin DP. The role of BRCA1 in
transcriptional regulation and cell cycle control. Oncogene
2006;25:5854–63.
101. Aprelikova ON, Fang BS, Meissner EG, et al. BRCA1-
associated growth arrest is RB-dependent. Proc Natl
Acad Sci USA 1999;96:11866–71.
102. Ting NS, Lee WH. The DNA double-strand break re-
sponse pathway: becoming more BRCAish than ever.
DNA Repair (Amst) 2004;3:935–44.
103. Turner N, Tutt A, Ashworth A. Hallmarks of ‘BRCAness’
in sporadic cancers. Nat Rev Cancer 2004;4:814–9.
104. Heine GF, Parvin JD. BRCA1 control of steroid receptor
ubiquitination. Sci STKE 2007;391:pe34.
105. Esteller M, Silva JM, Dominguez G, et al. Promoter hyper-
methylation and BRCA1 inactivation in sporadic breast
and ovarian tumors. J Natl Cancer Inst 2000;92:564–9.
106. Turner NC, Reis-Filho JS. Basal-like breast cancer and
the BRCA1 phenotype. Oncogene 2006;25:5846–53.
107. Saal LH, Gruvberger-Saal SK, Persson C, et al. Recurrent
gross mutations of the PTEN tumor suppressor gene in
breast cancers with deficient DSB repair. Nat Genet
2008;40:102–7.
108. Bradley A, Medina D. Introduction: BRCA1 and BRCA2
in mammary gland development and tumorigenesis. 
J Mammary Gland Biol Neoplasia 1998;3:363–4.
109. Furuta S, Jiang X, Gu B, et al. Depletion of BRCA1 
impairs differentiation but enhances proliferation of
mammary epithelial cells. Proc Natl Acad Sci USA
2005;102:9176–81.
110. Kubista M, Rosner M, Miloloza A, et al. Brca1 and 
differentiation. Mutat Res 2002;512:165–72.
111. Liu S, Ginestier C, Charafe-Jauffret E, et al. BRCA1 regu-
lates human mammary stem/progenitor cell fate. Proc
Natl Acad Sci USA 2008;105:1680–5.
112. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA
repair defect in BRCA mutant cells as a therapeutic
strategy. Nature 2005;434:917–21.
113. Bhattacharyya A, Ear US, Koller BH, et al. The breast
cancer susceptibility gene BRCA1 is required for subnu-
clear assembly of Rad51 and survival following treat-
ment with the DNA cross-linking agent cisplatin. J Biol
Chem 2000;275:23899–903.
114. Tassone P, Tagliaferri P, Perricelli A, et al. BRCA1 expres-
sion modulates chemosensitivity of BRCA1-defective
HCC1937 human breast cancer cells. Br J Cancer 2003;
88:1285–91.
115. Poole AJ, Li Y, Kim Y, et al. Prevention of Brca1-mediated
mammary tumorigenesis in mice by a progesterone 
antagonist. Science 2006;314:1467–70.
116. Shafee N, Smith CR, Wei S, et al. Cancer stem cells con-
tribute to cisplatin resistance in Brca1/p53-mediated
mouse mammary tumors. Cancer Res 2008;68:3243–50.
117. Daniels MJ, Wang Y, Lee M, et al. Abnormal cytokinesis
in cells deficient in the breast cancer susceptibility pro-
tein BRCA2. Science 2004;306:876–9.
118. Nathanson KL, Wooster R, Weber BL. Breast cancer 
genetics: what we know and what we need. Nat Med
2001;7:552–6.
119. Powell SN, Kachnic LA. Roles of BRCA1 and BRCA2 in
homologous recombination, DNA replication fidelity and
the cellular response to ionizing radiation. Oncogene
2003;22:5784–91.
120. Shamoo Y. Structural insights into BRCA2 function. Curr
Opin Struct Biol 2003;13:206–11.
121. Walsh T, Casadei S, Coats KH, et al. Spectrum of muta-
tions in BRCA1, BRCA2, CHEK2, and TP53 in families at
high risk of breast cancer. JAMA 2006;295:1379–88.
122. Mathew CG. Fanconi anaemia genes and susceptibility
to cancer. Oncogene 2006;25:5875–84.
123. Edwards SL, Brough R, Lord CJ, et al. Resistance to ther-
apy caused by intragenic deletion in BRCA2. Nature
2008;451:1111–5.
124. Sakai W, Swisher EM, Karlan BY, et al. Secondary muta-
tions as a mechanism of cisplatin resistance in BRCA2-
mutated cancers. Nature 2008;451:1116–20.
Breast cancer stem cells and tumor suppressor genes
J Formos Med Assoc | 2008 • Vol 107 • No 10 765
125. Lacroix M, Toillon RA, Leclercq G. p53 and breast 
cancer, an update. Endocr Relat Cancer 2006;13:
293–325.
126. Vogelstein B, Lane D, Levine AJ. Surfing the p53 net-
work. Nature 2000;408:307–10.
127. Vousden KH, Lu X. Live or let die: the cell’s response to
p53. Nat Rev Cancer 2002;2:594–604.
128. Zhao R, Gish K, Murphy M, et al. Analysis of p53-
regulated gene expression patterns using oligonucleotide
arrays. Genes Dev 2000;14:981–93.
129. Bargonetti J, Manfredi JJ. Multiple roles of the tumor
suppressor p53. Curr Opin Oncol 2002;14:86–91.
130. Sigal A, Rotter V. Oncogenic mutations of the p53 tumor
suppressor: the demons of the guardian of the genome.
Cancer Res 2000;60:6788–93.
131. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev
1996;10:1054–72.
132. Foray N, Marot D, Gabriel A, et al. A subset of ATM-
and ATR-dependent phosphorylation events requires the
BRCA1 protein. EMBO J 2003;22:2860–71.
133. Hohenstein P, Giles RH. BRCA1: a scaffold for p53 
response? Trends Genet 2003;19:489–94.
134. Crook T, Crossland S, Crompton MR, et al. p53 muta-
tions in BRCA1-associated familial breast cancer. Lancet
1997;350:638–9.
135. Borresen-Dale AL. TP53 and breast cancer. Hum Mutat
2003;21:292–300.
136. Meletis K, Wirta V, Hede SM, et al. p53 suppresses the
self-renewal of adult neural stem cells. Development
2006;133:363–39.
W.W. Hwang-Verslues, et al
766 J Formos Med Assoc | 2008 • Vol 107 • No 10
